Skip to content
Haemonetics LogoMedSurg

VASCADE MVP®

Early Ambulation. Simple. Proven.
VASCADE MVP® venous vascular closure system provides rapid haemostasis for electrophysiology (EP) procedures, enabling patients to get up earlier. VASCADE MVP system is easy to use and has demonstrated 0% major complicationsa in 1,223 patients in 5 EP clinical trials.1-5 In the AMBULATE pivotal trial1, VASCADE MVP system has been proven to reduce time to ambulation by 64%, improve patient satisfaction by 63% and reduce opioid use post procedure by 58%. The VASCADE MVP system is indicated for use in multi-stick and multi-limb catheter-based procedures.6

aMajor venous access site closure-related complications through the follow-up period.

Request Information

VASCADE MVP® System

Make a selection to learn more

Safer Procedure, Safer for the Patient1-5,a​

Ordering Information   |   AMBULATE Trial   |   Clinical Data 

The AMBULATE clinical study has shown that the use of VASCADE MVP® system reduces the time to ambulation. It was demonstrated that the median time to ambulation was 2.2 hours, which results in a 64% reduction in median time to ambulation compared to manual compression.1

View Brochure

A Simple Design for a Fast Learning Curve

Ordering Information   |   AMBULATE Trial 

The VASCADE MVP® system is indicated for use in catheter-based procedures6 with single or multiple access sites in one or both limbs and is an extravascular closure device to offer collagen with a dual method of action, mechanical and physiological. Using a single operator, the VASCADE MVP system is simple and easy to use and leaves no sutures or other materials behind in the vessel. The bioabsorbable thrombogenic patch expands by 13X to fill the tissue tract.7 The VASCADE MVP system allows for re-access, after 30 days, for repeat ablation procedures.
 

View Brochure

Proven by EPs

Ordering Information   |   AMBULATE Trial   |   Same Day Discharge 

The AMBULATE clinical studies have demonstrated 0% major complications8 in 1,223 total patients studied in 5 EP clinical trials, including 4 trials studying same day discharge paroxysmal and persistent AF ablation patients. 1-5​

The AMBULATE randomised clinical trial, comparing the VASCADE MVP system vs manual compression, has demonstrated 0% major complications and significantly lower rate of minor complications. It confirmed a 63% improvement in patient satisfaction. This might be driven by the 58% reduction in opioid use and a 51% reduction in pain medication use post procedure/following ablation.1​

View Brochure
Haemonetics Vascular Closure Vascade MVP

Simple and Easy to Use

✓ Single operator
✓ Indicated ​
    • For use in 6F to 12F ID (max 15F OD) 12 cm introducer sheathsa
    • For single or multiple access sites in one or both limbs
✓ 2 mechanisms of action​
    • Mechanical​
    • Physiological
✓ Extravascular design​
    • No permanent or intraluminal implants​
    • No sutures or material left in vessel​
✓ Bioabsorbable and thrombogenic collagen patch​​
    • Expands to fill tissue tract​
aOverall length of the sheath (including the hub) needs to be less than 15 cm

Haemonetics

Resource Centre 

Find the information you need as you browse through helpful, on-demand information to aid in your understanding of our vascular closure solutions.

Learn More

Featured Resources   View all resources

Instructions for Use

The VASCADE MVP® Venous Vascular Closure System is intended to seal the femoral vein access site(s) by delivering a resorbable Collagen Patch, extra-vascularly, at the venotomy site to aid in achieving hemostasis.

Read More

VASCADE MVP® Brochure

Our VASCADE MVP system provides rapid hemostasis for electrophysiology procedures, eliminating the need for manual compression and enabling patients to get up and moving earlier.

Read More

AMBULATE Trial

This prospective, multicenter, randomized study compared the efficacy and safety of VASCADE MVP® to manual compression for closing multiple access sites after catheter-based EP procedures.

Read More

AMBULATE Same Day Discharge Clinical Studies

This prospective, multicenter single arm registry evaluates procedural outcomes using VASCADE MVP® following atrial fibrillation interventions for patients who are discharged the same day. 
 

Read More

 

Ordering Information

To place an order please contact Customer Service.

* Major and Minor Venous Access Site Closure-Related Complications through 30-day follow-up. 
† Data on file at Haemonetics 

 

1. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol 2020; 6(1):111-124.
2. Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system. VASCADE MVP following multi-access cardiac ablation procedures. J Cardiovasc Electrophysiol 2021. 32(2): 191-99.
3. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781.
4/5. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. J Cardiovasc Electrophysiol 2022. https://doi. org/10.1111/jce.15763. NCT04203329.
6. Catheter-based cardiac ablations requiring two or more venous access sites within the same limb. See VASCADE MVP IFU 5686 Indications for Use.
7. Data on file at Haemonetics.
8. Major venous access site closure-related complications through the follow up.

 

COL-COPY-002322-FRCA(AA)  
 

Communiquez avec nous

Haemonetics Vascular Closure LinkedIn Haemonetics Vascular Closure Twitter

 

Les produits ne sont pas tous disponibles dans tous les marchés.